Comparison of Antidiabetic Medications during the Treatment of Atherosclerosis in T2DM Patients

Table 3

Sitagliptin group parameters of patients at the beginning and at the end of the study.

Parameters	Beginning ()	End ()	P
FBG (mmol/L)	7.59 ± 1.98	7.03 ± 1.93	0.27
SBP (mmHg)	132.87 ± 16.65	137.66 ± 13.10	0.22
HbA1c (%)	7.14 ± 1.16	6.50 ± 0.70	0.03
BMI (kg/m^2)	22.02 ± 1.14	21.93 ± 1.24	0.77
TC (mmol/L)	4.81 ± 0.94	4.56 ± 1.02	0.33
TG (mmol/L)	1.43 ± 1.14	1.36 ± 0.92	0.79
NHDL (mmol/L)	3.68 ± 0.90	3.20 ± 1.48	0.29
HDL (mmol/L)	1.00 ± 0.23	1.09 ± 0.25	0.30
LDL (mmol/L)	2.65 ± 0.87	2.53 ± 0.76	0.64
UA (μmol/L)	377.65 ± 81.56	379.00 ± 72.47	0.95
IMT (mm)	1.18 ± 0.16	1.15 ± 0.10	0.59
Cr (μmol/L)	87.35 ± 13.62	86.72 ± 16.82	0.87
IL-6 (pg/mL)	15.82 ± 6.20	12.78 ± 4.30	0.03
ADPN (ng/mL)	11.73 ± 3.67	12.15 ± 3.97	0.67